BRIEF-Beigene Provides Update On Phase 2 Clinical Trial Of Zanubrutinib In Patients With Covid-19-Related Pulmonary Distress
BRIEF-Beigene Provides Update On Phase 2 Clinical Trial Of Zanubrutinib In Patients With Covid-19-Related Pulmonary Distress
April 8 (Reuters) - Beigene Ltd 6160.HK :
* BEIGENE PROVIDES UPDATE ON PHASE 2 CLINICAL TRIAL OF ZANUBRUTINIB IN PATIENTS WITH COVID-19-RELATED PULMONARY DISTRESS
* BEIGENE LTD - TRIAL DID NOT MEET CO-PRIMARY EFFICACY ENDPOINTS; NO NEW SAFETY SIGNALS IDENTIFIED
* BEIGENE LTD - THERE WERE NO NEW OR ADDITIONAL SAFETY SIGNALS FOR ZANUBRUTINIB IDENTIFIED IN TRIAL
Source text for Eikon: Further company coverage:
April 8 (Reuters) - Beigene Ltd 6160.HK :
路透4月8日電-貝基恩有限公司6160.HK：
* BEIGENE PROVIDES UPDATE ON PHASE 2 CLINICAL TRIAL OF ZANUBRUTINIB IN PATIENTS WITH COVID-19-RELATED PULMONARY DISTRESS
*BEYGEN提供ZANUBRUTINIB治療新冠肺炎相關性肺窘迫患者的2期臨牀試驗的最新情況
* BEIGENE LTD - TRIAL DID NOT MEET CO-PRIMARY EFFICACY ENDPOINTS; NO NEW SAFETY SIGNALS IDENTIFIED
*BEYGEN LTD-試驗未達到聯合主要療效終點；沒有發現新的安全信號
* BEIGENE LTD - THERE WERE NO NEW OR ADDITIONAL SAFETY SIGNALS FOR ZANUBRUTINIB IDENTIFIED IN TRIAL
*BEYGEN LTD-在試驗中沒有發現ZANUBRUTINIB新的或額外的安全信號
Source text for Eikon: Further company coverage:
Eikon的源文本：進一步的公司報道：
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧